SDZNY OTC
Sandoz Group AG
1W: +1.1%
1M: +10.8%
3M: +14.4%
YTD: +31.5%
1Y: +52.6%
3Y: +223.3%
$96.00
-3.36 (-3.38%)
Weekly Expected Move ±3.5%
$90
$94
$97
$101
$104
Credit Risk of going bust: lower than 75% of companies Debt: 13.0% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $1.15 (down 99%), Sandoz Group AG would be worth roughly what it owes.
Total debt $6.20B against a stock market value of $41.54B.
Distance to default 8.62 (Merton model): prices to 2026-10-28, balance sheet 2026-06-30, debt counted $3.68B (short-term plus half of long-term), stock volatility 31.5%; Altman Z'' 2.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $6.20B against a stock market value of $41.54B.
Distance to default 8.62 (Merton model): prices to 2026-10-28, balance sheet 2026-06-30, debt counted $3.68B (short-term plus half of long-term), stock volatility 31.5%; Altman Z'' 2.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
#4
of 305
Drug Manufacturers - Specialty & Generic
Technical Signal Map
9 Bullish
0 Neutral
2 Bearish
SDZNY
$42B
Sandoz Group AG
BULLISH
+91
VTRS
$21B
Viatris Inc.
BULLISH
+100
MKGAF
$70B
Merck KGaA
BULLISH
+91
RDY
$11B
Dr. Reddy's Laboratories Limited
BULLISH
+84
HLN
$45B
Haleon plc
BULLISH
+78
ZTS
$33B
Zoetis Inc.
BULLISH
+78
TKPHF
$66B
Takeda Pharmaceutical Company Limited
BULLISH
+59
TEVA
$46B
Teva Pharmaceutical Industries Limited
BULLISH
+40
SGIOY
$16B
Shionogi & Co., Ltd.
BULLISH
+34
IPSEY
$58B
Ipsen S.A.
LEAN BEAR
-13
ELAN
$11B
Elanco Animal Health Incorporated
BEARISH
-40
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| SDZNY Sandoz Group AG | $42B | 64.7 | 7.2 | 10.1 | 1.9 | 29.1 | 6 | BULLISH | 52.6 |
| VTRS Viatris Inc. | $21B | -52.1 | -2.8 | -0.3 | -3.2 | 4.4 | 7 | BULLISH | 82.2 |
| MKGAF Merck KGaA | $70B | 26.8 | 8.1 | 8.1 | 9.0 | -0.4 | 7 | BULLISH | 27.1 |
| RDY Dr. Reddy's Laboratories Limited | $11B | 40.0 | 7.5 | 6.0 | 10.7 | -3.1 | 4 | BULLISH | -2.2 |
| HLN Haleon plc | $45B | 20.6 | 10.1 | 8.4 | 13.6 | 1.3 | 8 | BULLISH | 8.9 |
| ZTS Zoetis Inc. | $33B | 12.8 | 64.4 | 26.3 | 28.0 | 1.4 | 6 | BULLISH | -47.1 |
| TKPHF Takeda Pharmaceutical Company Limited | $66B | 55.9 | 2.5 | 2.8 | 9.3 | 3.3 | 6 | BULLISH | 30.7 |
| TEVA Teva Pharmaceutical Industries Limited | $46B | 63.4 | 9.7 | 9.3 | -13.9 | 4.1 | 7 | BULLISH | 103.9 |
| SGIOY Shionogi & Co., Ltd. | $16B | 9.8 | 13.6 | 9.9 | 50.6 | 10.3 | 5 | BULLISH | 16.7 |
| IPSEY Ipsen S.A. | $58B | 24.7 | 11.5 | 16.3 | 17.5 | 10.2 | 6 | LEAN BEAR | 19.2 |
| ELAN Elanco Animal Health Incorporated | $11B | -55.2 | -3.0 | 3.7 | 3.9 | 12.0 | 5 | BEARISH | 1.7 |
| SDZNY Sandoz Group AG | $42B | 64.7 | 7.2 | 10.1 | 1.9 | 29.1 | 6 | BULLISH | 52.6 |
| WAT Waters Corporation | $45B | 118.6 | 1.9 | 1.5 | -8.3 | 52.5 | 5 | BULLISH | 35.6 |
| MTD Mettler-Toledo International Inc. | $33B | 38.1 | -736.4 | 46.7 | 22.7 | 6.9 | 8 | BULLISH | 19.7 |
| EW Edwards Lifesciences Corporation | $51B | 52.7 | 9.5 | 17.9 | 13.9 | 14.6 | 6 | BULLISH | 13.6 |
| ILMN Illumina, Inc. | $41B | 53.4 | 32.4 | 18.2 | 17.9 | 4.9 | 7 | BULLISH | 187.8 |
| A Agilent Technologies, Inc. | $49B | 35.7 | 21.0 | 14.9 | 19.3 | 8.6 | 7 | BULLISH | 23.8 |
| IDXX IDEXX Laboratories, Inc. | $44B | 39.5 | 74.2 | 46.5 | 27.8 | 12.8 | 9 | BULLISH | -13.1 |
| GEHC GE HealthCare Technologies Inc. | $32B | 19.6 | 16.3 | 13.3 | 11.2 | 1.8 | 6 | BULLISH | -3.2 |
| OTSKY Otsuka Holdings Co., Ltd. | $42B | 15.8 | 13.8 | 12.2 | 16.7 | 10.9 | 8 | BULLISH | 41.0 |
| IQV IQVIA Holdings Inc. | $46B | 33.5 | 21.7 | 9.6 | 7.9 | 8.8 | 8 | BULLISH | 28.4 |
| BIIB Biogen Inc. | $37B | 1.6 | 1.9 | 3.1 | -0.7 | 3.1 | 4 | BULLISH | 62.2 |
| ALC Alcon Inc. | $34B | 53.7 | 2.9 | 3.6 | 0.0 | 7.8 | 6 | BULLISH | -8.3 |
| ONC BeOne Medicines AG | $40B | 25.4 | 14.7 | 57.2 | 13.9 | 34.3 | 8 | BULLISH | 18.4 |
| SEMHF Siemens Healthineers AG | $53B | 21.5 | 12.1 | 8.4 | 11.6 | 10.0 | 9 | BULLISH | -19.6 |
| CNC Centene Corp. | $35B | 22.7 | 6.8 | 6.4 | -0.1 | 4.8 | 8 | BULLISH | 102.3 |
| HUM Humana Inc. | $51B | 38.7 | 6.8 | 17.2 | 1.7 | 18.3 | 4 | NEUTRAL | 40.9 |
| BAYRY Bayer AG | $48B | -26.2 | -5.5 | 6.4 | 2.0 | -1.5 | 4 | NEUTRAL | 60.6 |
| DSNKY Daiichi Sankyo Company, Limited | $33B | 19.7 | 15.1 | 12.5 | 11.9 | 17.4 | 5 | BEARISH | -37.9 |
| RSMDF ResMed Inc. | $36B | 24.0 | 24.3 | 25.3 | 26.2 | 9.9 | 7 | BEARISH | -15.5 |
| RVMD Revolution Medicines, Inc. | $40B | -21.3 | -79.1 | 186.4 | — | — | 1 | BEARISH | 225.4 |
| RVMDW Revolution Medicines, Inc. Warrant | $40B | -21.3 | -79.1 | 186.4 | — | — | 1 | BEARISH | 2287.5 |
| SDZNY Sandoz Group AG | $42B | 64.7 | 7.2 | 10.1 | 1.9 | 29.1 | 6 | BULLISH | 52.6 |
| JNJ Johnson & Johnson | $636B | 41.1 | 20.0 | 21.3 | 0.8 | 7.8 | 6 | BULLISH | 43.3 |
| AMGN Amgen Inc. | $237B | 27.9 | 91.5 | 19.5 | 23.6 | 9.2 | 8 | BULLISH | 59.5 |
| GILD Gilead Sciences, Inc. | $193B | -61.2 | -20.6 | -3.4 | -134.5 | 5.5 | 5 | BULLISH | 33.0 |
| DHR Danaher Corporation | $162B | 38.2 | 8.3 | 6.3 | 18.8 | 5.5 | 7 | BULLISH | 6.7 |
| REGN Regeneron Pharmaceuticals, Inc. | $83B | 19.4 | 14.0 | 12.9 | 30.2 | 9.3 | 7 | BULLISH | 39.1 |
| EW Edwards Lifesciences Corporation | $51B | 52.7 | 9.5 | 17.9 | 13.9 | 14.6 | 6 | BULLISH | 13.6 |
| WAT Waters Corporation | $45B | 118.6 | 1.9 | 1.5 | -8.3 | 52.5 | 5 | BULLISH | 35.6 |
| MTD Mettler-Toledo International Inc. | $33B | 38.1 | -736.4 | 46.7 | 22.7 | 6.9 | 8 | BULLISH | 19.7 |
| WST West Pharmaceutical Services, Inc. | $28B | 51.3 | 19.1 | 19.0 | 17.7 | 12.4 | 9 | BULLISH | 40.9 |
| DGX Quest Diagnostics Incorporated | $27B | 24.1 | 15.2 | 10.2 | 10.1 | 9.1 | 8 | BULLISH | 36.3 |
| VTRS Viatris Inc. | $21B | -52.1 | -2.8 | -0.3 | -3.2 | 4.4 | 7 | BULLISH | 82.2 |
| MEDP Medpace Holdings, Inc. | $19B | 37.7 | 117.9 | 1953.7 | 19.2 | 20.4 | 9 | BULLISH | 16.1 |
| RVTY Revvity, Inc. | $18B | 78.7 | 3.2 | 3.5 | 7.1 | 5.5 | 6 | BULLISH | 70.2 |
| CRL Charles River Laboratories International, Inc. | $17B | -77.3 | -7.7 | 6.9 | -0.1 | -0.7 | 4 | BULLISH | 91.6 |
| EXEL Exelixis, Inc. | $16B | 20.1 | 44.4 | 69.0 | 33.7 | 9.2 | 8 | BULLISH | 65.7 |
| ASND Ascendis Pharma A/S | $15B | 18.5 | 121.1 | 76.2 | 61.0 | 114.8 | 7 | BULLISH | 22.8 |
| ICLR ICON Public Limited Company | $14B | 36.6 | 3.5 | 5.5 | 3.5 | 2.0 | 6 | BULLISH | 17.6 |
| HALO Halozyme Therapeutics, Inc. | $14B | 36.9 | 173.7 | 32.5 | 47.8 | 41.2 | 5 | BULLISH | 97.5 |
| PMCUF Pro Medicus Limited | $13B | 77.5 | 75.0 | 68.1 | 68.7 | 22.8 | 7 | BULLISH | -25.7 |
| ABBV AbbVie Inc. | $505B | 80.7 | -206.4 | 23.5 | 21.3 | 10.4 | 7 | BULLISH | 25.4 |
| TMO Thermo Fisher Scientific Inc. | $249B | 37.1 | 13.4 | 8.6 | 14.2 | 8.3 | 8 | BULLISH | 25.1 |
| PFE Pfizer Inc. | $171B | 38.9 | 5.0 | 11.3 | -1.6 | -0.2 | 7 | BULLISH | 21.1 |
| MDT Medtronic Plc | $122B | 23.2 | 10.7 | 7.8 | 15.1 | 9.8 | 9 | BULLISH | 4.1 |
| MKGAF Merck KGaA | $70B | 26.8 | 8.1 | 8.1 | 9.0 | -0.4 | 7 | BULLISH | 27.1 |
| NTRA Natera, Inc. | $58B | -312.1 | -12.5 | -23.6 | -8.9 | 37.8 | 6 | BULLISH | 120.8 |
| LZAGY Lonza Group AG | $54B | -409.0 | 13.5 | 10.5 | 17.5 | -9.7 | 8 | BULLISH | 4.4 |
| BDX Becton, Dickinson and Company | $54B | 58.8 | 3.8 | 4.1 | 7.6 | -2.6 | 6 | BULLISH | 4.9 |
| A Agilent Technologies, Inc. | $49B | 35.7 | 21.0 | 14.9 | 19.3 | 8.6 | 7 | BULLISH | 23.8 |
| ILMN Illumina, Inc. | $41B | 53.4 | 32.4 | 18.2 | 17.9 | 4.9 | 7 | BULLISH | 187.8 |
| RPRX Royalty Pharma plc | $28B | 26.9 | 12.4 | 10.6 | 2.7 | 10.0 | 6 | BULLISH | 75.0 |
| LH Labcorp Holdings Inc. | $27B | 29.4 | 11.4 | 8.7 | 6.9 | 6.0 | 8 | BULLISH | 32.1 |
| ZBH Zimmer Biomet Holdings, Inc. | $19B | 23.3 | 6.4 | 5.9 | 9.1 | 8.6 | 6 | BULLISH | -6.5 |
| GKOS Glaukos Corporation | $11B | -61.7 | -26.0 | -12.7 | -9.9 | 41.5 | 3 | BULLISH | 139.8 |
| QGEN Qiagen N.V. | $10B | 25.8 | 11.9 | 11.2 | 19.3 | 3.0 | 8 | BULLISH | 4.0 |
| NVS Novartis AG | $287B | 30.0 | 30.6 | 16.8 | 22.7 | 0.8 | 5 | BULLISH | 20.9 |
| SNY Sanofi | $100B | 23.1 | 5.7 | 6.4 | 2.8 | 13.4 | 6 | BULLISH | -17.8 |
| GH Guardant Health, Inc. | $23B | -52.3 | 171.6 | -88.3 | -35.9 | 42.7 | 6 | BULLISH | 157.7 |
| RDY Dr. Reddy's Laboratories Limited | $11B | 40.0 | 7.5 | 6.0 | 10.7 | -3.1 | 4 | BULLISH | -2.2 |
| ORINY Orion Oyj | $30B | 23.0 | 53.6 | 46.3 | 26.9 | 22.6 | 7 | BULLISH | 34.8 |
| HLN Haleon plc | $45B | 20.6 | 10.1 | 8.4 | 13.6 | 1.3 | 8 | BULLISH | 8.9 |
| IDXX IDEXX Laboratories, Inc. | $44B | 39.5 | 74.2 | 46.5 | 27.8 | 12.8 | 9 | BULLISH | -13.1 |
| ZTS Zoetis Inc. | $33B | 12.8 | 64.4 | 26.3 | 28.0 | 1.4 | 6 | BULLISH | -47.1 |
| GEHC GE HealthCare Technologies Inc. | $32B | 19.6 | 16.3 | 13.3 | 11.2 | 1.8 | 6 | BULLISH | -3.2 |
| PHG Koninklijke Philips N.V. | $26B | 20.7 | 10.2 | 7.6 | 8.8 | -1.1 | 6 | BULLISH | -6.4 |
| CLPBY Coloplast A/S | $17B | 39.0 | 18.5 | 70.9 | 19.9 | -2.9 | 5 | BULLISH | -22.4 |
| SNN Smith & Nephew plc | $13B | 19.6 | 11.8 | 9.9 | 9.8 | 5.3 | 7 | BULLISH | -15.6 |
| GMED Globus Medical, Inc. | $11B | 20.5 | 11.8 | 12.3 | 19.2 | 19.7 | 8 | BULLISH | 28.5 |
| RHHBF Roche Holding AG | $393B | 26.0 | 40.2 | 24.6 | 22.6 | 27.8 | 6 | BULLISH | 30.5 |
| ABT Abbott Laboratories | $179B | 38.0 | 10.7 | 7.3 | 7.4 | 8.1 | 5 | BULLISH | -19.3 |
| CSLLY CSL Limited | $134B | -26.3 | -15.2 | 13.1 | -40.2 | 1.7 | 4 | BULLISH | 3.0 |
| SYK Stryker Corporation | $118B | 31.2 | 16.5 | 11.6 | 19.4 | 8.5 | 9 | BULLISH | -20.8 |
| GNMSF Genmab A/S | $28B | 45.1 | 3.9 | 11.9 | 26.2 | -82.1 | 4 | BULLISH | 95.1 |
| ROIV Roivant Sciences Ltd. | $26B | -97.7 | -6.2 | -217.5 | -13164.4 | -67.6 | 1 | BULLISH | 97.3 |
| ALGN Align Technology, Inc. | $11B | 22.3 | 10.2 | 12.3 | 10.3 | 4.4 | 7 | BULLISH | 13.2 |
| PODD Insulet Corp. | $10B | 27.8 | 26.0 | 21.3 | 11.8 | 29.4 | 9 | BULLISH | -54.3 |
| MRNA Moderna, Inc. | $80B | -26.8 | -39.0 | -90.1 | -539.3 | -27.2 | 2 | BULLISH | 706.4 |
| NBIX Neurocrine Biosciences, Inc. | $15B | 20.6 | 22.1 | 16.0 | 15.1 | 34.4 | 6 | BULLISH | -2.3 |
| BBIO BridgeBio Pharma, Inc. | $13B | -19.8 | 32.4 | 57.9 | -62.5 | 202.4 | 4 | BULLISH | 11.4 |
| LLY Eli Lilly and Company | $1.2T | 43.1 | 102.4 | 39.2 | 30.9 | 49.6 | 9 | BULLISH | 56.1 |
| VRTX Vertex Pharmaceuticals Incorporated | $133B | 30.6 | 23.5 | 28.3 | 33.0 | 10.6 | 6 | BULLISH | 26.1 |
| SOAGY Sartorius AG ADR | $92B | 92.6 | 7.7 | 6.6 | 7.1 | 4.3 | 7 | BULLISH | 17.5 |
| IQV IQVIA Holdings Inc. | $46B | 33.5 | 21.7 | 9.6 | 7.9 | 8.8 | 8 | BULLISH | 28.4 |
| OTSKY Otsuka Holdings Co., Ltd. | $42B | 15.8 | 13.8 | 12.2 | 16.7 | 10.9 | 8 | BULLISH | 41.0 |
| BIIB Biogen Inc. | $37B | 1.6 | 1.9 | 3.1 | -0.7 | 3.1 | 4 | BULLISH | 62.2 |
| TRUMY Terumo Corporation | $22B | 21.2 | 11.0 | 9.6 | 22.6 | 15.6 | 5 | BULLISH | -10.4 |
| SONVF Sonova Holding AG | $20B | 39.2 | 20.4 | 17.2 | 19.7 | -7.1 | 6 | BULLISH | 19.7 |
| BAX Baxter International Inc. | $13B | -12.5 | -15.7 | -1.6 | 4.3 | 5.4 | 3 | BULLISH | 10.2 |
| AVTR Avantor, Inc. | $12B | 33.3 | -9.7 | -2.5 | 2.3 | -1.6 | 6 | BULLISH | 10.4 |
| TECH Bio-Techne Corporation | $11B | 62.1 | 9.0 | 8.9 | 17.0 | -0.4 | 7 | BULLISH | 13.3 |
| WILYY Demant A/S | $12B | 47.1 | 15.9 | 10.9 | 9.1 | 10.6 | 5 | BULLISH | 42.5 |
| HOCPY HOYA Corporation | $56B | 33.3 | 27.3 | 46.1 | 25.7 | 14.2 | 6 | BULLISH | 6.6 |
| TKPHF Takeda Pharmaceutical Company Limited | $66B | 55.9 | 2.5 | 2.8 | 9.3 | 3.3 | 6 | BULLISH | 30.7 |
| RGEN Repligen Corporation | $11B | -879.5 | -0.6 | -1.4 | -18.4 | 13.8 | 4 | BULLISH | 14.6 |
| CI Cigna Corporation | $81B | 12.2 | 15.5 | 11.8 | 2.3 | 7.7 | 8 | BULLISH | -4.0 |
| ALC Alcon Inc. | $34B | 53.7 | 2.9 | 3.6 | 0.0 | 7.8 | 6 | BULLISH | -8.3 |
| STE STERIS plc | $23B | 27.9 | 11.4 | 9.7 | 13.4 | 8.4 | 8 | BULLISH | -4.8 |
| SRTOY Sartorius Stedim Biotech S.A. | $228B | 66.3 | 7.4 | 6.2 | 12.5 | 4.4 | 8 | BULLISH | 0.5 |
| ISRG Intuitive Surgical, Inc. | $160B | 53.1 | 18.0 | 22.6 | 17.1 | 20.5 | 7 | BULLISH | -19.4 |
| FSNUY Fresenius SE & Co. KGaA | $117B | 16.8 | 8.1 | 5.6 | 6.4 | 5.9 | 7 | BULLISH | -20.6 |
| ESLOF EssilorLuxottica S.A. | $94B | 32.9 | 6.5 | 5.2 | 10.6 | 7.4 | 6 | BULLISH | -46.6 |
| SEMHF Siemens Healthineers AG | $53B | 21.5 | 12.1 | 8.4 | 11.6 | 10.0 | 9 | BULLISH | -19.6 |
| ONC BeOne Medicines AG | $40B | 25.4 | 14.7 | 57.2 | 13.9 | 34.3 | 8 | BULLISH | 18.4 |
| UTHR United Therapeutics Corporation | $25B | 19.4 | 19.3 | 31.3 | 42.5 | 2.5 | 6 | BULLISH | 39.3 |
| SAUHY Straumann Holding AG | $19B | 41.5 | 17.3 | 21.7 | 18.1 | 3.0 | 6 | BULLISH | 4.5 |
| BMXXY bioMérieux S.A. | $12B | 23.2 | 11.2 | 8.9 | 11.5 | -3.5 | 7 | BULLISH | -22.0 |
| ENSG The Ensign Group, Inc. | $10B | 26.6 | 17.1 | 8.6 | 7.0 | 17.5 | 7 | BULLISH | -1.3 |
| CAH Cardinal Health, Inc. | $58B | 33.7 | -60.5 | 92.8 | 0.6 | 14.2 | 8 | BULLISH | 50.9 |
| UNH UnitedHealth Group Incorporated | $375B | 23.2 | 15.9 | 13.5 | 3.6 | 3.3 | 7 | BULLISH | 12.0 |
| ERFSF Eurofins Scientific SE | $17B | 28.7 | 12.8 | 4.6 | 8.2 | 3.3 | 6 | BULLISH | 32.5 |
| TEVA Teva Pharmaceutical Industries Limited | $46B | 63.4 | 9.7 | 9.3 | -13.9 | 4.1 | 7 | BULLISH | 103.9 |
| RCDTF Recordati Industria Chimica e Farmaceutica S.p.A. | $12B | 21.8 | 24.9 | 15.4 | 16.7 | 9.2 | 7 | BULLISH | -9.2 |
| ALPMF Astellas Pharma Inc. | $30B | 12.3 | 21.4 | 16.9 | 22.1 | 17.3 | 7 | BULLISH | 66.3 |
| SGIOY Shionogi & Co., Ltd. | $16B | 9.8 | 13.6 | 9.9 | 50.6 | 10.3 | 5 | BULLISH | 16.7 |
| DVA DaVita Inc. | $12B | 15.8 | -149.4 | 17.9 | 7.5 | 6.4 | 8 | BULLISH | 42.0 |
| CHGCF Chugai Pharmaceutical Co., Ltd. | $74B | 21.7 | 25.1 | 40.8 | 35.5 | 16.1 | 8 | BULLISH | -8.4 |
| CNC Centene Corp. | $35B | 22.7 | 6.8 | 6.4 | -0.1 | 4.8 | 8 | BULLISH | 102.3 |
| BIOVF Swedish Orphan Biovitrum AB | $16B | 25.0 | 3.4 | 17.2 | 14.0 | 13.3 | 4 | BULLISH | 37.3 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $16B | 58.9 | 23.3 | 27.3 | 20.6 | 5.0 | 6 | BULLISH | 34.9 |
| UCBJY UCB S.A. | $58B | 23.4 | 20.7 | 16.4 | 26.0 | 25.3 | 6 | LEAN BULL | 7.8 |
| COO The Cooper Companies, Inc. | $12B | 20.3 | 6.8 | 6.3 | 40.6 | 4.7 | 6 | LEAN BULL | -18.4 |
| AZN AstraZeneca PLC | $266B | 25.3 | 22.0 | 15.0 | 16.3 | 8.6 | 9 | LEAN BULL | 4.1 |
| CVS CVS Health Corp. | $120B | 23.5 | 6.2 | 4.9 | 2.8 | 7.4 | 8 | LEAN BULL | 9.1 |
| HCA HCA Healthcare, Inc. | $102B | 56.2 | -124.7 | 23.3 | 8.4 | 7.3 | 6 | LEAN BULL | -0.8 |
| TEM Tempus AI, Inc. | $12B | -53.6 | -67.4 | -19.8 | 1.5 | 50.4 | 4 | LEAN BULL | -16.4 |
| JDHIY JD Health International Inc. | $16B | 16.1 | 10.3 | 31.0 | 8.4 | 19.6 | 6 | LEAN BULL | -43.9 |
| FMS Fresenius Medical Care AG & Co. KGaA | $12B | 12.2 | 7.3 | 6.7 | 4.5 | -0.5 | 7 | NEUTRAL | -16.8 |
| ARGX argenx SE | $55B | 41.8 | 26.0 | 50.1 | 29.8 | 162.5 | 7 | NEUTRAL | 7.5 |
| THC Tenet Healthcare Corporation | $22B | 10.3 | 53.3 | 19.1 | 14.7 | 5.4 | 7 | NEUTRAL | 24.2 |
| HUM Humana Inc. | $51B | 38.7 | 6.8 | 17.2 | 1.7 | 18.3 | 4 | NEUTRAL | 40.9 |
| MCK McKesson Corporation | $117B | 25.6 | -148.0 | 237.7 | 0.6 | 8.8 | 8 | NEUTRAL | 18.5 |
| INCY Incyte Corporation | $23B | 14.4 | 30.7 | 82.1 | 35.0 | 26.9 | 8 | NEUTRAL | 25.6 |
| AAVXF Abivax S.A. | $12B | -17.1 | -221.8 | 440.6 | — | -133.5 | 4 | NEUTRAL | 57.0 |
| CHJTF CSPC Pharmaceutical Group Limited | $14B | 10.5 | 20.7 | 36.7 | 32.8 | 88.1 | 6 | NEUTRAL | 13.3 |
| BMY Bristol-Myers Squibb Company | $126B | 13.3 | 46.7 | 17.8 | 25.6 | 3.1 | 8 | NEUTRAL | 45.9 |
| IHHHF IHH Healthcare Berhad | $15B | 30.9 | 7.3 | 6.1 | 8.1 | 7.1 | 5 | NEUTRAL | 43.7 |
| BAYRY Bayer AG | $48B | -26.2 | -5.5 | 6.4 | 2.0 | -1.5 | 4 | NEUTRAL | 60.6 |
| ALNY Alnylam Pharmaceuticals, Inc. | $30B | 38.1 | 100.7 | -152.8 | 12.7 | 95.1 | 6 | NEUTRAL | -51.4 |
| COR Cencora, Inc. | $63B | 24.0 | 104.3 | 26.5 | 0.9 | 5.1 | 7 | LEAN BEAR | -3.3 |
| EHC Encompass Health Corporation | $12B | 18.8 | 25.5 | 16.7 | 9.6 | 9.5 | 9 | LEAN BEAR | -4.0 |
| IPSEY Ipsen S.A. | $58B | 24.7 | 11.5 | 16.3 | 17.5 | 10.2 | 6 | LEAN BEAR | 19.2 |
| SUVPF Sartorius AG | $19B | 92.6 | 7.7 | 6.7 | 7.1 | 3.6 | 7 | LEAN BEAR | -0.5 |
| GSK GSK plc | $102B | 15.3 | 25.5 | 18.8 | 5.2 | 5.0 | 7 | LEAN BEAR | 12.3 |
| BTSG BrightSpring Health Services, Inc. Common Stock | $12B | 41.6 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | LEAN BEAR | 75.8 |
| ELV Elevance Health Inc. | $95B | 17.6 | 11.6 | 16.2 | 2.7 | 3.6 | 7 | LEAN BEAR | 21.6 |
| MOH Molina Healthcare, Inc. | $11B | -324.8 | -1.2 | -44.2 | 0.4 | -2.1 | 5 | LEAN BEAR | 22.1 |
| BSX Boston Scientific Corporation | $66B | 17.1 | 15.5 | 11.6 | 16.7 | 13.5 | 8 | BEARISH | -58.6 |
| DSNKY Daiichi Sankyo Company, Limited | $33B | 19.7 | 15.1 | 12.5 | 11.9 | 17.4 | 5 | BEARISH | -37.9 |
| WXIBF WuXi Biologics (Cayman) Inc. | $26B | 31.7 | 10.6 | 16.0 | 20.7 | 16.0 | 9 | BEARISH | 31.1 |
| ELAN Elanco Animal Health Incorporated | $11B | -55.2 | -3.0 | 3.7 | 3.9 | 12.0 | 5 | BEARISH | 1.7 |
| NONOF Novo Nordisk A/S | $172B | 9.7 | 59.8 | 35.2 | 26.7 | 5.6 | 5 | BEARISH | -28.8 |
| RSMDF ResMed Inc. | $36B | 24.0 | 24.3 | 25.3 | 26.2 | 9.9 | 7 | BEARISH | -15.5 |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | $12B | 41.6 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | BEARISH | 70.7 |
| PEN Penumbra, Inc. | $13B | 77.8 | 11.4 | 13.6 | 8.9 | 17.6 | 6 | BEARISH | 28.4 |
| SMMT Summit Therapeutics Inc. | $12B | -14.1 | -192.5 | 1714.4 | — | — | 3 | BEARISH | -19.0 |
| IVBXF Innovent Biologics, Inc. | $20B | 98.2 | 6.9 | 67.2 | 14.5 | 35.4 | 6 | BEARISH | -2.6 |
| OCPNF Olympus Corporation | $12B | 24.8 | 10.6 | 12.7 | 7.9 | 7.8 | 5 | BEARISH | -9.8 |
| BMRN BioMarin Pharmaceutical Inc. | $11B | 147.4 | 1.2 | 1.4 | 4.5 | 11.2 | 4 | BEARISH | 6.3 |
| BNTX BioNTech SE | $22B | -11.5 | -9.3 | -18.0 | -777.3 | -8.2 | 2 | BEARISH | -17.0 |
| INSM Insmed Incorporated | $20B | -23.6 | -87.2 | -364.8 | -3.1 | 185.8 | 5 | BEARISH | -40.9 |
| MRK Merck & Co., Inc. | $358B | 112.0 | 7.0 | 6.1 | -8.0 | 4.5 | 4 | BEARISH | 61.6 |
| WUXAY WuXi AppTec Co., Ltd. | $68B | 15.4 | 31.6 | 40.7 | 50.0 | 31.2 | 8 | BEARISH | 65.8 |
| RVMD Revolution Medicines, Inc. | $40B | -21.3 | -79.1 | 186.4 | — | — | 1 | BEARISH | 225.4 |
| RVMDW Revolution Medicines, Inc. Warrant | $40B | -21.3 | -79.1 | 186.4 | — | — | 1 | BEARISH | 2287.5 |
| MDLN Medline Inc. | $30B | 37.6 | 3.2 | 4.4 | 0.8 | — | 4 | BEARISH | — |
| DXCM DexCom, Inc. | $29B | 30.4 | 38.5 | 42.9 | 19.0 | 15.5 | 9 | BEARISH | 11.3 |
| GIKLY Grifols, S.A. | $15B | 16.0 | 8.4 | 7.4 | 8.2 | -0.2 | 6 | BEARISH | -19.0 |
| MDGL Madrigal Pharmaceuticals, Inc. | $10B | -33.4 | -53.3 | -778.9 | -15.9 | 149.0 | 2 | BEARISH | -1.1 |
| SOLV Solventum Corporation | $15B | 10.0 | 34.0 | 18.1 | 4.2 | -0.9 | 7 | BEARISH | 13.7 |
| UHS Universal Health Services, Inc. | $11B | 7.1 | 21.0 | 12.5 | 7.7 | 10.0 | 8 | BEARISH | -19.5 |
| JAZZ Jazz Pharmaceuticals plc | $14B | 13.5 | 22.1 | 26.4 | 16.0 | 12.6 | 8 | BEARISH | 47.2 |
| SBMFF Sino Biopharmaceutical Limited | $12B | 31.2 | 21.1 | 40.0 | 17.7 | 28.2 | 7 | BEARISH | -22.9 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
SDZNY vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F